Jonathan Sockolosky, PhD

Director, Company Value Creation at Curie.Bio

Jonathan Sockolosky is currently the Director of Company Value Creation for Curie.Bio, a founder-centric, seed stage biotechnology investing firm that reduces the barrier for founders to build new therapeutic companies and foster innovation. Previously Jonathan served as a Senior Scientist in the Department of Antibody Engineering at Genentech. His research group focused on the development of next generation immune modulating therapeutics for oncology and cancer immunology, particularly cytokine biology and engineering. Prior to Genentech, Jonathan was a Principal Scientist at ALX Oncology, a clinical stage biotechnology company developing CD47/SIRPa antagonists for cancer immunotherapy. Jonathan received his BS/MS in Biomedical Engineering from the University of Michigan, his PhD in Pharmaceutical Sciences from UCSF, and did postdoctoral research at Stanford in the lab of K. Christopher Garcia where he invented orthogonal IL-2 cytokine-receptor pairs for cell therapy under development by Synthekine.